Loading...
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocyt...
Na minha lista:
| Udgivet i: | JACC Basic Transl Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5753417/ https://ncbi.nlm.nih.gov/pubmed/29308438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2016.06.006 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|